These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 34622806)

  • 1. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
    Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
    Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
    Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation.
    Bai J; Yokomizo-Nakano T; Kubota S; Sun Y; Kanai A; Iimori M; Harada H; Iwama A; Sashida G
    Oncogene; 2021 Feb; 40(8):1531-1541. PubMed ID: 33452460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.
    Sun J; He X; Zhu Y; Ding Z; Dong H; Feng Y; Du J; Wang H; Wu X; Zhang L; Yu X; Lin A; McDonald T; Zhao D; Wu H; Hua WK; Zhang B; Feng L; Tohyama K; Bhatia R; Oberdoerffer P; Chung YJ; Aplan PD; Boultwood J; Pellagatti A; Khaled S; Kortylewski M; Pichiorri F; Kuo YH; Carlesso N; Marcucci G; Jin H; Li L
    Cell Stem Cell; 2018 Sep; 23(3):355-369.e9. PubMed ID: 30146412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
    Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
    J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC; Agosto-Peña J
    Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].
    Zhu C; Ma Y; Xu XP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):873-8. PubMed ID: 24989313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability.
    Pattabiraman DR; Sun J; Dowhan DH; Ishii S; Gonda TJ
    Mol Cancer Res; 2009 Sep; 7(9):1477-86. PubMed ID: 19737967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
    Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
    Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
    Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
    BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
    Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
    J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological
    Kon A; Yamazaki S; Nannya Y; Kataoka K; Ota Y; Nakagawa MM; Yoshida K; Shiozawa Y; Morita M; Yoshizato T; Sanada M; Nakayama M; Koseki H; Nakauchi H; Ogawa S
    Blood; 2018 Feb; 131(6):621-635. PubMed ID: 29146882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
    Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
    Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.